COROS Dura 2 Solar Review: Huge Battery, $549 Price, Buggy Launch
The COROS Dura 2 Solar bike computer more than doubles the Dura's price to $549. DC Rainmaker's review finds long battery life but broken rerouting at launch.
Fitbit Air Health Guardian: BP and Insulin Trends Need Premium
Google Health 5.11 brings Health Guardian blood pressure and insulin resistance trends to Fitbit Air, behind Premium. What the features need and measure.
Oura Cardio Effort: Weekly Load Bands and Automatic VO2 Max
Oura Cardio Effort scores weekly cardio load against a personal baseline, and automatic VO2 Max needs no walking test. How Oura's new training metrics work.
Garmin Edge Explore 3 vs Explore 3 Plus: $399 or $499 for Voice?
Garmin's Edge Explore 3 and Explore 3 Plus add route options, beginner coaching and Plus-only voice control. What the extra $100 buys and who should pick each.
Garmin Edge 1060: What $100 More Buys Over the Edge 1050
The Garmin Edge 1060 adds voice control, a smaller case and new routing for $799. What changed from the Edge 1050, and which cyclists should wait.
Garmin Fenix 8 Update 23.40 Fixes the Dead Heart Rate Sensor
Garmin Fenix 8 update 23.40 fixes the heart rate sensor failure from 23.39, but reached only 20% of watches at first. What broke, and what owners should do.
Apple Watch on a Huawei Phone: Notifications Yes, Health Data No
An Apple Watch can now show calls and texts from a Huawei phone via a HarmonyOS app. What works, why health data stays on the iPhone, and who it suits.
Garmin MARQ Gen 3 Review: Fenix 9 Features at $2,500 and Up
The Garmin MARQ Gen 3 adds LTE, satellite SOS, a flashlight and a 3,000-nit display from $2,500. DC Rainmaker's tests, and who should pay over a Fenix 9.
Polar H10 Resonance Breathing: SYMPATHETIC Adds HRV and ECG
SYMPATHETIC is a free iPhone app that pairs Polar H10 resonance breathing with live HRV and ECG views. What it measures, its limits, and who it suits.
Fitbit Edge: The Charge 6 Successor Fixes GPS but Costs $179
The Fitbit Edge replaces the Charge 6 with working GPS, an altimeter and a swappable battery, but drops Google Pay and costs $179. Who should upgrade.
Mito's $249 Heart Scan: What a Coronary Calcium Score Actually Tells You
Mito Health now offers a $249 coronary artery calcium scan, which shows existing arterial plaque. Who the 2026 ACC/AHA guidelines say should consider one.
Best Outdoor Saunas: What to Know Before You Build (Site Prep, Foundation, and Hardwired 240V)
An outdoor sauna is a building project: site prep, foundation, a 240V circuit, and drainage come first. How to choose an outdoor sauna for your site.
Choose Your Home Sauna Heat System Before You Choose a Brand
Traditional, infrared, hybrid, and portable home saunas solve different problems. Why choosing the heat system before the brand avoids the costliest mistake.
Blood Pressure and Longevity: What Peter Attia's AMA #48 Gets Right About Measurement
Blood pressure is one of three primary drivers of atherosclerosis — yet most people check it once a year. Attia's AMA #48 rebroadcast makes the case for treating it as a daily metric.
Zone 2 Training: Why Time-Constrained Athletes May Be Better Off Skipping It
Peter Attia reframes Zone 2 as a volume tool, not a metabolic must-do — and the implications for busy people are bigger than expected.
KardiaMobile 6L: The Study That Found Twice as Many Arrhythmias as Hospital Monitors
A University of Rochester cohort study published in JACC Advances found AliveCor's KardiaMobile 6L detected nearly twice the arrhythmia rate of traditional short-duration ECG monitors in 350 patients over 30 days.
GDF-15 and P-Tau217: The Biomarkers That Warn You Before You Feel Anything
New biomarker research is shifting the question from 'what's wrong?' to 'what's coming?' GDF-15 as a cellular stress signal and p-tau217 for pre-symptomatic Alzheimer's risk represent a new category of early detection — but their limitations matter as much as their promise.
GDF-15 and P-tau217: The Biomarkers That Signal Breakdown Before You Feel It
Two biomarkers — GDF-15 for cellular stress and P-tau217 for Alzheimer's risk — can flag physiological strain years before symptoms appear. Here's what they measure, what trends reveal, and why a single reading misses the point.
NMR Blood Testing: One Blood Sample, Four Different Risk Scores
A single NMR blood scan reveals heart disease, insulin resistance, inflammation, and mortality risk — the inventor explains why one draw beats a standard panel.
Peter Attia's Framework for Environmental Threats to Longevity: Air, Noise, and Light
AMA #87 applies Attia's 80/20 principle to chronic environmental exposures — PM2.5, noise, and artificial light — and which interventions actually move the longevity needle.
Heat Training Boosts Hemoglobin — But Can It Make You Faster?
Heat training reliably raises hemoglobin mass by 2–5%. But 5 of 6 trials find no clear performance payoff in VO₂max or sport results. Here's what the evidence actually shows.
Scientists Reversed 'Permanent' Aging Damage in Human Tissue. Here's What Was Fixed.
A Nature Communications study showed an engineered enzyme (CMLase) removed advanced glycation end products from human arterial, skin, and lens tissue — reversing damage long considered irreversible.
Google's SensorFM: What a 1-Trillion-Minute Wearable Dataset Changes
Google's new foundation model for wearable sensors outperformed prior models on 34 of 35 health tasks — and what it means for the future of passive health monitoring.
Medtronic and Corsano Are Building the Hospital-to-Home Wearable Stack
Medtronic's integration of Corsano's FDA-cleared multi-parameter wearable into its HealthCast platform extends clinical monitoring from pre-op through home recovery — targeting alarm fatigue along the way.
GARM's Klotho Longevity Residency Brought 22 Participants to Honduras. Here's What They're Testing.
A four-day longevity residency at the Kimpton Grand Roatán included a proprietary Klotho intervention, blood sampling before and after, and researchers from MIT and Harvard. GARM is betting that Klotho is the next longevity biomarker to watch.
Peter Attia: High HDL Cholesterol Doesn't Protect Your Heart. It Might Hurt It.
HDL-C has been called 'good cholesterol' for decades. Peter Attia's latest analysis unpacks why the clinical evidence never supported the label — and why very high HDL-C levels may signal elevated cardiovascular risk, not lower.
Sky Labs' CART BP Pro Ring Heads to Europe After 260K+ South Korean Prescriptions
Sky Labs is launching its cuffless blood pressure monitoring ring in Europe and the UK, backed by CE-MDR certification and a 260,000+ prescription track record in South Korea.
VERVE-102 and the Beginning of the End of Atherosclerosis
A Phase I trial published in the New England Journal of Medicine shows VERVE-102, a one-time base-editing gene therapy, can cut PCSK9 protein levels by up to 88% and LDL cholesterol by up to 62% — potentially permanently — in high-risk cardiovascular patients.
Scribe Therapeutics' STX-1150: Silencing PCSK9 Epigenetically Without Editing Your DNA
Scribe's STX-1150 cuts LDL 50%+ in primates for 18 months from a single dose — silencing PCSK9 epigenetically, not by altering the DNA sequence itself.
Diathrive + KardiaComplete: The Cardiometabolic Stack Getting FDA-Grade ECG Into Diabetes Care
People with Type 2 diabetes face 2-3x higher AFib risk, yet most digital health platforms treat heart and glucose monitoring separately. The Diathrive-KardiaComplete integration changes that.
Sky Labs CART: A Cuffless BP Ring With Real Regulatory Approval
Sky Labs' CART ring cleared UK MHRA and EU CE-MDR after 1,700 Korean hospitals and 150,000 prescriptions. What cuffless 24-hour BP monitoring actually requires.
Peter Attia AMA #84: Family History, NAD Skepticism, and Dementia Risk
Peter Attia AMA #84: why family health history outperforms genetic testing, his stance on NAD supplements, and minimum effective strength training dose.
Lipid-Lowering Pharmacotherapy: The Decision That Actually Determines Outcomes
92 million Americans take statins, but which lipid-lowering drug you take matters less than matching it to your dominant cholesterol pathway. Here's the framework.
Obicetrapib: The Drug Targeting Both Heart Disease and Alzheimer's at Once
A CETP inhibitor in late-stage trials cut LDL by up to 50% while reducing Alzheimer's biomarkers. The BROADWAY trial data may represent a new category of longevity drug.